Intralesional targeted alpha therapy for metastatic melanoma

Cancer Biology and Therapy

Volumn 4, Issue 12, 2005, Pages 1318-1324

  Allen, Barry J ^a,c   Raja, Chand ^a   Rizvi, Syed ^a   Li, Yong ^a   Tsui, Wendy ^a   Graham, Peter ^a   Thompson, John F ^b,d   Reisfeld, Ralph A ^e   Kearsley, John ^a   Morgenstern, Alfred ^f   Apostolidis, Christos ^f  

^a ST GEORGE HOSPITAL   (Australia)

^b ROYAL PRINCE ALFRED HOSPITAL   (Australia)

^c UNIVERSITY OF NEW SOUTH WALES   (Australia)

^d UNIVERSITY OF SYDNEY   (Australia)

^e SCRIPPS RESEARCH INSTITUTE   (United States)

^f JOINT RESEARCH CENTRE   (Italy)

Author keywords

9.2.27 monoclonal antibody; Alpha radiation; Bi 213; Melanoma; Metastasis; Targeted alpha therapy; Toxicity

Indexed keywords

ALPHA IMMUNOCONJUGATE; ANTIBODY CONJUGATE; MELANOMA INHIBITORY ACTIVITY PROTEIN; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY 9.2.27; PROTEIN; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CELL DEATH; CELL PROLIFERATION; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE CALCULATION; DOSE RESPONSE; DRUG CLEARANCE; DRUG EFFICACY; DRUG ELIMINATION; DRUG SAFETY; DRUG UPTAKE; ELECTROLYTE BALANCE; FEMALE; HISTOPATHOLOGY; HUMAN; MALE; MAXIMUM TOLERATED DOSE; MELANOMA; METASTASIS; PHASE 1 CLINICAL TRIAL; PROTEIN BLOOD LEVEL; RADIATION MONITORING; TREATMENT OUTCOME;

EID: 31144463014     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.4161/cbt.4.12.2251     Document Type: Article

References (41)

1. Allen BJ, Blagojevic N. Alpha and beta emitting radiolanthanides in targeted cancer therapy: the potential role for Terbium-149. Nuclear Medicine Communications 1996; 17:40-7.
2. Kassis AI, Harris CR, Adelstein SJ, Ruth TJ, Lambrecht R, Wolf AP. The in vitro radiobiology of Astatine-211 decay. Radiation Research 1986; 105:27-36.
3. Horak E, Hartmann F, Garmestani K, Wu C, Brechbiel M, Gansow O, Landolfi N, and Waldmann T. Radioimmunotherapy targeting the HER2/neu oncoprotein expressed on an ovarian tumor using the alpha-emitting radionuclide-conjugated monoclonal antibody Lead-212-DOTA-AE1. J. Nuclear Med. 1997; 38:1944-50.
4. Larsen RH, Akabani G, Welsh P, Zalutsky MR. The cytotoxicity and microdosimetry of astatine-211-labeled chimeric monoclonal antibodies in human glioma and melanoma cells in vitro. Radiation Research 1998; 149:155-62.
5. Sgouros G, Ballangurd AM, Jurcic JG. Pharmacokinetics and dosimetry of an alpha particle emitter labelled antibody Bi-213-HuM195 (anti CD33) in patients with leukemia. J Nuclear Medicine 1999; 40:1935-46.
6. Bumol TF, Reisfeld RA. Unique glycoprotein-proteoglycan complex defined by monoclonal antibody on human melanoma cells. Proceedings National Academia Science USA. 1982; 79:1245-9.
7. Gupta RK, Moreton DL. Monoclonal antibody based ELISA to detect glycoprotein tumour-associated-antigen-specific immune complexes in cancer patients. J Clinical Laboratory Anal. 1992; 6:329-36.
8. Schlingemann RO, Rietveld FJ, De Waal RM, Ferrone S, Ruiter DJ. Expression of the high molecular weight melanoma-associated antigen by pericytes during angiogenesis in tumours and in healing wounds. American Journal Pathology. 1990;136:1393-1405.
9. Pouly S, Prat A, Blain M, Olivier A, Antel JP. NG2 immunoreactivity on human brain endothelial cells. Acta Neuropathologica. 2001:102;313-20.
10. Pouly S, Becher B, Blain M, Antel JP. Expression of a homologue of rat NG2 on human microglia. Glia 1999;27:259-268.
11. Burg MA, Grako KA, Stallcup WB. Expression of the NG2 proteoglycan enhances the growth and metastatic properties of melanoma cells. J. Cell. Physiology 1998;177:299-312.
12. Chekenya M, Hjelstuen M, Enger PO, Thorsen F, Jacob A, Probst B, Haraldseth O, Pilkington G, Butt A, Levine JM, Bjerkvig R. NG2 proteoglycan promotes angiogenesis-dependent tumor growth in CNS by sequestering angiostatin. The FASEB Journal. 2002; 16:586-8.
13. Tanaka K, Nogava S, Ito D, Suzuki S, Dembo T, Kosakai A, Fucuuchi Y. Activation of NG2-positive oligodendrocyte progenitor cells during post-ischemic reperfusion in the rat brain. Neuroreport. 2001; 12:2169-74.
14. Hwang KM, Fodstad O, Oldham RK, Morgan AC. Radiolocalization of xenografted human malignant melanoma by a monoclonal antibody (9.2.27) to a melanoma-associated antigen in nude mice. Cancer Research 1985; 45:4150-5.
15. Schrappe M, Klier FG, Spiro RC, Waltz TA, Reisfeld RA, Gladson CL. Correlation of chondroitin sulfate proteoglycan expression on proliferating brain capillary endothelial cells with the malignant phenotype of astroglial cells. Cancer Research 1991; 51:4986-93.
16. Oldham RK, Foon KA, Woodhouse CS, Schroff RW, Abrahms PG, Fer M, Schoenberger CS, Farrell M, Kimball E. Monoclonal antibody therapy of malignant melanoma: in vivo localization in cutaneous metastasis after intravenous administration. Journal of Clinical Oncology 1984; 2:1235-44.
17. Li Y, Madigan MC, Lai K, Conway R M, Billson FA, Crouch R, Allen BJ. Human uveal melanoma expresses NG2 immunoreactivity. British J Ophthalmology 2003; 87:629-32.
18. Rizvi SMA, Samir S, Goozee G, Allen BJ. Radioimmunoconjugates for targeted alpha therapy of malignant melanoma. Melanoma Research 2000; 10:281-90.
19. Allen BJ, Rizvi SMA, Tian Z. Preclinical targeted alpha therapy for subcutaneous melanoma. Melanoma Research 2001; 11:175-82.
20. Allen BJ. Can alpha-immunotherapy succeed where other systemic modalities have failed? Nuclear Medicine Communications1999; 20:205-7.
21. Jurcic JG, Larsen SM, Sgouros G. Mcdevitt MR, Finn RD, Divgi CR, Ballangrud AM. Targeted ± particle immunotherapy for myeloid leukemia. Blood 2002; 100:1233-9.
22. Feinendegen LE, McClure JJ. Alpha emitters for medical therapy-workshop of the United States Department of Energy, Meeting Report, Denver, Colorado. 1996; May 30-31.
23. Larsen RH, Bruland OS. Intratumour injection of immunoglobulins labelled with the alpha particle emitter At-211: analysis of tumour retention, microdistribution and growth delay. British Journal Cancer 1998; 77:1115-22.
24. Emami B, Lyman J, Brown A, Coia L, Goitein M, Munzenrider JE, Shank B, Solin LJ, Wesson M. Tolerance of normal tissue to therapeutic irradiation. International J Radiation Oncol. Biol. Phys., 1991; 21:109-22.
25. Mettler FA, Upton AC. Medical Effects of Ionizing Radiation, 2nd edition, WB Saunders Company. Philadelphia, US. 1995; Chapter 6:214.
26. Cassady JR. Clinical radiation nephropathy. International Journal of Radiation Oncology and Biological Physics 1995; 31:1249-56.
27. Rubin P and Casarett GW. Concepts of clinical radiation pathology. In: (3rd ed.), Dalrymple G, Gaulden M, Kallomorgen G, Vogel H, Editors. Medical Radiation Biology Vol. 8, W. B. Saunders, Philadelphia 1973:160-89.
28. Gorczyca W, Gong J, Ardelt B, Traganos F, Darzynkiewicz Z. The cell cycle related differences in susceptibility of HL-60 cells to apoptosis induced by various antitumor agents. Cancer Research 1993; 53:3186-92.
29. Hall PA, Levison DA. Assessment of Cell Proliferation in Histologic Material. 1990. J Clinical Pathology 1990; 43:184-92.
30. Nikula TK, McDevitt MR, Finn RD, Wu C, Kozak RW, Garmestani K, Brechbiel MW, Curcio MJ, Pippin CG, Tiffany-Jones L, Geerlings MW Sr., Apostolidis C, Molinet R, Geerlings MW Jr, Gansow OA, Scheinberg DA. Alpha-emitting bismuth cyclohexylbenzyl DTPA constructs of recombinant humanized anti-CD33 antibodies: pharmacokinetics, bioactivity, toxicity and chemistry. Journal of Nuclear Medicine 1999; 40:166-76.
31. Bosserhoff A K, Kaufmann M, Kaluza B, Bartke I, Zirngibl H, Hein R, Stolz W, Buettner R. Melanoma inhibiting activity, a novel serum marker for progression of malignant melanoma. Cancer Research 1997; 57:3149-53.
32. Bosserhoff AK, Buetner R. Expression, function and clinical relevance of MIA (Melanoma Inhibitory Activity). Histology Histopathology 2002; 17:289-300.
33. Shawler DL, Bartholomew RM, Smith LM, Dillman RO. Human response to multiple injections of murine monoclonal IgG. J. Immunology1985; 135:1530-35.
34. Allen BJ. Targeted alpha therapy: evidence for efficacy of alpha-immunoconjugates in the management of micrometastatic cancer. Australasian Radiology 1999; 43:480-6.
35. Feldman ED, Pingpank JF, Alexander HR. Regional treatment options for patients with ocular melanoma metastatic to the liver. Annals of Surgical Oncology 2003; 11:290-297.
36. Snyder W, Ford M, Warner G, Watson S. "S" absorbed dose per unit cumulated activity for selected radionuclides and organs. MIRD Pamphlet No 11. Society of Nuclear Medicine, New York, NY, 1975.
37. Stabin MG. MIRDOSE: the personal computer software for use in internal dose assessment in nuclear medicine. J Nucl Med 1996; 37:538-46.
38. Stabin MG, Tagesson M, Thomas SR, Ljungberg M, Strand SE. Radiation dosimetry in nuclear medicine. Applied Radiation and Isotopes 1999; 50:73-87.
39. Report of the RBE Committee to the International Commissions on Radiological Units and Measurements, Health Physics 1963; 9:357.
40. Tsui W. Phase 1 clinical trial for targeted alpha therapy of metastatic subcutaneous melanoma using Bi-213-cDTPA-9.2.27 MAb. Honours Thesis, UNSW 2001.
41. Lederer CM and Shirley VS. Editors: Table of Isotopes, Seventh Edition, University of California, John Wiley & Sons, NY, 1978:1363.